ArticleEuropean heart journal2020
Reduction in ACE2 may mediate the prothrombotic phenotype in COVID-19.
Article in European heart journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis.Microvascular research · 2021Pooled it
- The association between baseline viral load and long-term risk in patients with COVID-19 in Hong Kong: a territory-wide study.Scientific reports · 2024Article
- Effects of physical training on coagulation parameters, interleukin-6, and angiotensin-converting enzyme-2 in COVID-19 survivors.Scientific reports · 2024Article
- Article
- The possible mechanism and research progress of ACE2 involved in cardiovascular injury caused by COVID-19: a review.Frontiers in cardiovascular medicine · 2024Review
- Long COVID: current status in Japan and knowledge about its molecular background.Global health & medicine · 2022Review
- Impairment of Anti-Aggregatory Responses to Nitric Oxide and Prostacyclin: Mechanisms and Clinical Implications in Cardiovascular Disease.International journal of molecular sciences · 2022Review
- Hypertension and its management in COVID-19 patients: The assorted view.International journal of cardiology. Cardiovascular risk and prevention · 2021Review
- Rapid Detection and Inhibition of SARS-CoV-2-Spike Mutation-Mediated Microthrombosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- The SARS-CoV-2/Receptor Axis in Heart and Blood Vessels: A Crisp Update on COVID-19 Disease with Cardiovascular Complications.Viruses · 2021Review
- The Fight against COVID-19 on the Multi-Protease Front and Surroundings: Could an Early Therapeutic Approach with Repositioning Drugs Prevent the Disease Severity?Biomedicines · 2021Review
- Evidence for Biological Age Acceleration and Telomere Shortening in COVID-19 Survivors.International journal of molecular sciences · 2021Article
- Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19.Scientific reports · 2021Article
- Stroke in patients with COVID-19: Clinical and neuroimaging characteristics.Neuroscience letters · 2021Review
- ACE2 down-regulation may contribute to the increased thrombotic risk in COVID-19.European heart journal · 2020Article
- Understanding COVID-19: in the end it is the endothelium-what else?European heart journal · 2020Article
- Heparan sulfate consumption as a potential mechanism of intra-cardiac thrombosis in SARS-CoV-2 infection.Heart & lung : the journal of critical careArticle
Corrections and comments
- Commented on by
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.